It’s unusual to have the FDA chase down a pharma company and ask them apply for a new drug indication. But Pfizer went through just that and has now quietly revealed a label expansion for blockbuster breast cancer med Ibrance.
The FDA has extended Ibrance’s approval in combination with an aromatase inhibitor to include newly diagnosed HR-positive, HER2-negative metastatic breast cancer patients regardless of menopausal status, Pfizer said Tuesday.
